Proof-of-concept Study Evaluating the Safety and Efficacy of EBP921 in Delta Hepatitis (HDV)
Status:
Terminated
Trial end date:
2013-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the optimal dose of EBP921 by comparing the efficacy
and safety of 2 dose regimens in patients with chronic HDV.